EVOVEST GLOBAL EQUITY ETF UNITS CAD
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 5.1K
- Market Cap
- $1.3B
- Website
- http://evotec.com
- Introduction
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
News
Duke-NUS Receives $1.5M to Advance AI-Powered Antifibrotic Drug Discovery Platform
65LAB has awarded $1.5 million to Professor Enrico Petretto at Duke-NUS Medical School to advance a breakthrough Systems Genetics platform for developing first-in-class antifibrotic therapies.
Dewpoint Therapeutics Cuts 70% of Workforce, Refocuses on Lead Cancer Drug DPTx3186
Dewpoint Therapeutics laid off approximately 70% of its workforce and consolidated operations to Boston following a high burn rate despite raising $287 million across three funding rounds.
Evotec Sells Toulouse Biologics Facility to Sandoz for $300M in Strategic Asset-Light Transition
Evotec SE and Sandoz AG signed a non-binding agreement for the potential $300 million sale of the Just-Evotec Biologics facility in Toulouse, France.
Sernova and Eledon Partner to Advance Type 1 Diabetes Bio-hybrid Organ Therapy with Novel Immunosuppression
Sernova Biotherapeutics and Eledon Pharmaceuticals announced a collaboration to evaluate tegoprubart, an anti-CD40L antibody, in Sernova's Phase 1/2 Cell Pouch Bio-hybrid Organ clinical trial for type 1 diabetes.
Evotec Joins NURTuRE-AKI Consortium to Advance Multi-Omics Research for Acute Kidney Injury Treatment
Evotec has joined the NURTuRE-AKI consortium led by Kidney Research UK to establish the world's most comprehensive patient cohort for acute kidney injury research.
Sernova Biotherapeutics Chairman Ross Haghighat Resigns as Company Advances Type 1 Diabetes Cell Therapy
Sernova Biotherapeutics announced the resignation of Chairman Ross Haghighat, effective May 24, 2025, with the board accepting his departure and thanking him for his leadership.
Peptone and Evotec Form Strategic Alliance to Develop Novel Therapeutics Targeting Intrinsically Disordered Proteins
Peptone and Evotec have established a strategic partnership to accelerate the development of small molecule therapeutics targeting intrinsically disordered proteins (IDPs) across multiple therapeutic areas, including oncology and immunology.
Gates Foundation Awards Evotec $2.5M Grant to Advance Next-Generation Tuberculosis Treatments
The Gates Foundation has awarded Evotec a $2.5 million grant to support the development of next-generation tuberculosis treatment regimens, building on their five-year partnership.
Evotec and Bristol Myers Squibb Achieve Major Milestone in Molecular Glue Degrader Collaboration, Triggering $75M Payment
Evotec SE announced significant progress in its strategic protein degradation collaboration with Bristol Myers Squibb, triggering performance-based payments totaling $75 million.
SynaptixBio Selects Antisense Oligonucleotide Candidate for Rare Disease H-ABC Clinical Trials
Oxford-based SynaptixBio has identified SB H-19642, an antisense oligonucleotide drug candidate, to advance into clinical trials for H-ABC, a rare and currently incurable form of TUBB4A-related leukodystrophy.